Kamada's ATT system does well in Ph II

Kamada, an Israeli biopharmaceutical company engaged in the development, manufacturing and marketing of specialty therapeutics, reported positive data from its Phase II study evaluating inhaled alpha-1 antitrypsin (AAT) delivered via an investigational eFlow nebulizer system, in the treatment of cystic fibrosis.

The Phase II, double-blind, placebo-controlled study was designed to evaluate safety of the inhaled product in CF patients and to assess its potential efficacy in decreasing lung inflammation. Results revealed that daily inhalation of AAT for a period of 28 days reduced lung inflammation in comparison to placebo, as measured by neutrophil count and neutrophil elastase levels. There were no serious adverse events reported in either the active or the placebo group and no safety concerns were raised. Kamada plans to present the study data at an upcoming major medical meeting.

Chief executive David Tsur said: "this product is the next generation of AAT treatment that may be used as an effective treatment for CF patients, to improve their quality of life. We believe that the inhaled product will offer significant advantages to CF patients and we are very optimistic about its further development in this and in other respiratory patient populations."